BST:2QG

Stock Analysis Report

Quantum Genomics Société Anonyme

Executive Summary

Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases.


Snowflake Analysis

Adequate balance sheet with limited growth.

Share Price & News

How has Quantum Genomics Société Anonyme's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2QG's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.4%

2QG

-0.7%

DE Biotechs

-0.6%

DE Market


1 Year Return

n/a

2QG

-13.2%

DE Biotechs

-20.9%

DE Market

Return vs Industry: Insufficient data to determine how 2QG performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 2QG performed against the German Market.


Shareholder returns

2QGIndustryMarket
7 Day-4.4%-0.7%-0.6%
30 Day-27.3%-8.2%-18.6%
90 Dayn/a-21.0%-26.2%
1 Yearn/a-12.9%-13.2%-18.6%-20.9%
3 Yearn/a14.5%13.2%-19.0%-25.8%
5 Yearn/a-9.5%-11.8%-21.2%-31.8%

Price Volatility Vs. Market

How volatile is Quantum Genomics Société Anonyme's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Quantum Genomics Société Anonyme undervalued compared to its fair value and its price relative to the market?

3.12x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 2QG's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 2QG's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 2QG is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 2QG is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2QG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2QG is good value based on its PB Ratio (3.1x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Quantum Genomics Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-34.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2QG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2QG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2QG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2QG's revenue (75.4% per year) is forecast to grow faster than the German market (4% per year).

High Growth Revenue: 2QG's revenue (75.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2QG is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Quantum Genomics Société Anonyme performed over the past 5 years?

-28.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2QG is currently unprofitable.

Growing Profit Margin: 2QG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 2QG is unprofitable, and losses have increased over the past 5 years at a rate of -28.2% per year.

Accelerating Growth: Unable to compare 2QG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2QG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).


Return on Equity

High ROE: 2QG has a negative Return on Equity (-81.8%), as it is currently unprofitable.


Next Steps

Financial Health

How is Quantum Genomics Société Anonyme's financial position?


Financial Position Analysis

Short Term Liabilities: 2QG's short term assets (€15.6M) exceed its short term liabilities (€4.5M).

Long Term Liabilities: 2QG's short term assets (€15.6M) exceed its long term liabilities (€973.1K).


Debt to Equity History and Analysis

Debt Level: 2QG's debt to equity ratio (0.01%) is considered satisfactory.

Reducing Debt: 2QG had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: 2QG has a low level of unsold assets or inventory.

Debt Coverage by Assets: 2QG's debt is covered by short term assets (assets are 13816.9x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if 2QG has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 2QG has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Quantum Genomics Société Anonyme's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2QG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2QG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2QG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2QG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2QG's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Jean-Philippe Milon (59yo)

2s

Tenure

Dr. Jean-Philippe Milon, PhD., has been the Chief Executive Officer at Quantum Genomics Société Anonyme since April 06, 2018 and has been its Director since June 27, 2019. Dr. Milon served as the Chief Ope ...


Leadership Team

NamePositionTenureCompensationOwnership
Lionel Ségard
Founder & Chairmanno data€244.15k1.59% 605.0k
Jean-Philippe Milon
CEO & Director2yrsno datano data
Benoît Gueugnon
Chief Financial Officer0.25yrno datano data
Bruno Besse
Chief Medical Officer3yrsno datano data

2.0yrs

Average Tenure

Experienced Management: 2QG's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Lionel Ségard
Founder & Chairmanno data€244.15k1.59% 605.0k
Jean-Philippe Milon
CEO & Director2yrsno datano data
Howard Dittrich
Member of Scientific & Clinical Advisory Board4.17yrsno datano data
Christian Béchon
Directorno datano datano data
Mark Caulfield
Member of Scientific & Clinical Advisory Boardno datano datano data
Alexandre Persu
Member of Scientific & Clinical Advisory Boardno datano datano data
Keith Ferdinand
Member of Scientific & Clinical Advisory Board4.17yrsno datano data
Henry Black
Member of Scientific & Clinical Advisory Board4.17yrsno datano data
Toshiro Fujita
Member of Scientific and Clinical Advisory Board2.75yrsno datano data
Frans Leenen
Member of Scientific and clinical advisory board2.17yrsno datano data

3.5yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 2QG's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46%.


Top Shareholders

Company Information

Quantum Genomics Société Anonyme's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Quantum Genomics Société Anonyme
  • Ticker: 2QG
  • Exchange: BST
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €38.166m
  • Shares outstanding: 18.62m
  • Website: https://www.quantum-genomics.com

Number of Employees


Location

  • Quantum Genomics Société Anonyme
  • 33, rue Marbeuf
  • Paris
  • Ile-de-France
  • 75008
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALQGCENXTPA (Euronext Paris)YesOrdinary SharesFREURJul 2009
0D1JLSE (London Stock Exchange)YesOrdinary SharesGBEURJul 2009
2QGBST (Boerse-Stuttgart)YesOrdinary SharesDEEURJul 2009
2QGDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2009

Biography

Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug for the treatment of hypertension and heart failure, as well as acts on the inhibition of Aminopeptidase A in the brain. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy; and QGC006 to optimize the treatment of hypertension with a monotherapy drug. The company is based in Paris, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/04 03:25
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.